Glatiramer acetate or interferon-β for multiple sclerosis?: A guide to drug choice

CNS Drugs

Volumn 11, Issue 4, 1999, Pages 289-306

  Milo, Ron ^a   Panitch, Hillel ^b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADVERSE DRUG REACTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG METABOLISM; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT OUTCOME;

EID: 0032893142     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911040-00005     Document Type: Review

References (91)

1. 1. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995; 32: 121-82
2. 2. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997; 120: 865-916
3. 3. Miller SD, Karpus WJ. The immunopathogenesis and regulation of T cell-mediated demyelinating diseases. Immunol Today 1994; 15: 356-61
4. 4. Hartung HP. Pathogenesis of multiple sclerosis. In: Abramsky O, Ovadia H, editors. Frontiers in multiple sclerosis. London: Martin Dunitz Ltd, 1997: 45-60
5. 5. Panitch HS. Investigational drug therapies for treatment of multiple sclerosis. Mult Scler 1996; 2: 66-77
6. 6. Panitch HS, Folus JS, Johnson KP. Beta interferon prevents HLA class II antigeninduction by gamma interferon in MS [abstract]. Neurology 1989; 39 Suppl. 1: 171
7. 7. Jiang H, Milo R, Yong VW, et al. Interferon beta-1b reduces IFN-gamma-induced antigen presenting capacity of human glial and B cells. J Neuroimmunol 1995; 61: 17-25
8. 8. Noronha A, Toscas A, Jensen MA. Interferon-β decreases T cell activation and interferon-gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-54
9. 9. Rudick RA, Carpenter CS, Cookfair DL, et al. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology 1993; 43: 2080-7
10. 10. Gene K, Reder AT. IFNβ-1b reverses elevated lymphocyte B7-1 in MS [abstract]. J Neuroimmunol 1995; 52 Suppl. 1: 20
11. 11. Reder AT. IFN-β and IFN-γ modify expression of monocyte surface proteins [abstract]. J Interferon Res 1991; 11 Suppl. 1: 121
12. 12. Milo R, Panitch H. Additive effects of Copolymer-1 and interferon-beta on the immune response to myelin basic protein. J Neuroimmunol 1995; 61: 185-93
13. 13. Panitch HS, Folus JS, Johnson KP. Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis [abstract]. Ann Neurol 1987; 22: 139
14. 14. Noronha A, Toscas A, Jensen M. IFN-beta downregulates IFN-gamma production by activated T-cells in MS [abstract]. Neurology 1991; 41 Suppl. 1: 219
15. 15. Noronha A, Toscas A, Jensen M. IFN-β modulates immune function: implication for multiple sclerosis [abstract]. J Immunol 1993; 150: 48A
16. 16. Abu-Khabar KS, Armstrong JA, Ho M. Type 1 interferons (IFN-α and -β) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukoc Biol 1992; 52: 165-72
17. 17. Noronha A, Jensen M, Toscas A. TGF-beta activity in MS: effect of IFN-beta [abstract]. Neurology 1993; 43 Suppl. 2: A355
18. 18. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-27
19. 19. Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-300
20. 20. Cousens LP, Orange JS, Su HC, et al. Interferon α/β inhibition of interleukin 12 and interferon-γ production in vitro and endogenously during viral infection. Proc Natl Acad Sci U S A 1997; 94: 634-9
21. 21. Reder AT, Lowy MT. Interferon-β treatment does not elevate cortisol in multiple sclerosis. J Interferon Res 1992; 12: 195-8
22. 22. Pozzilli C, Bastianello S, Koudriavsteva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 251-8
23. 23. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
24. 24. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood brain barrier disruption demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-9
25. 25. Calabresi PA, Pelfrey CM, Tranquill LR, et al. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49: 1111-6
26. 26. Miller A, Lanir N, Shapiro S, et al. Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases. J Neuroimmunol 1996; 64: 151-61
27. 27. Dhib-Jalbut S, Jiang H, Williams GJ. The effect of interferon beta-1b on lymphocyte-endothelial cell adhesion. J Neuroimmunol 1996; 71: 215-22
28. 28. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1β. Ann Neurol 1997; 41: 669-74
29. 29. Corsini E, Gelati M, Dufour A, et al. Effects of beta-IFN-1β treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. J Neuroimmunol 1997, 79: 76-83
30. 30. Lepert DD, Waubant E, Burk MR, et al. Interferon beta-1β inhibits gelatinase secretion and in vitro migration of human T-cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52
31. 31. Stuve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effect on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63
32. 32. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990; 27: 207-10
33. 33. Noronha A, Toscas A, Arnason BGW, et al. IFN-beta augments in vivo suppressor function in MS [abstract]. Neurology 1994; 44 Suppl. 2: A212
34. 34. Antel J, Brown M, Nicholas MK, et al. Activated suppressor cell function in multiple sclerosis-clinical correlations. J Neuroimmunol 1988; 17:323-30
35. ser in healthy volunteers and its effect on serum neopterin. Pharm Res 1993; 10: 567-72
36. 36. Khan OA, Xia Q, Bever CT, et al. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996; 46: 1639-43
37. 37. Revel M, Chebath J. Interferon-activated genes. Trends Biochem Sci 1986; 11: 166-70
38. 38. Goldstein D, Sielaff KM, Storer BE, et al. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. J Natl Cancer Inst 1989; 81: 1061-8
39. 39. Witt PL, Storer BE, Bryan GT, et al. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J Immunother 1993; 13: 191-200
40. 40. Knobler RL, Greenstein JJ, Johnson KP, et al. Systemic recombinant interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six year follow-up. J Interferon Res 1993; 13: 333-40
41. 41. The IFNB Multiple Sclerosis Study Group. Interferon-beta 1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
42. 42. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85
43. 43. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
44. 14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double blind, placebo-controlled trial. Neurology 1995; 45: 1268-76
45. 45. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 1989; 112: 1419-28
46. 46 European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
47. 47. Paty DW, Li DKB, The UBC MS/MRI Study Group, et al. Interferon-beta 1b is effective in relapsing-remitting multiple sclerosis. II. MRT analysis results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7
48. 48. Dayal AS, Jensen MA, Lledo A, et al. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995; 45: 2173-7
49. 49. Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving IFN beta-1b for MS: report of a consensus conference. Neurology 1996; 46: 12-8
50. 50. Knobler RL, Kelley CL, Trantas F, et al. Interferon beta-1b induced ulcerative skin lesions in MS [abstract]. J Neuroimmunol 1994; 54: 173
51. 51. Panitch H, Milo R. Interferon therapy for multiple sclerosis. Int MS J 1995; 2: 12-25
52. 52. Interferon beta-1b prescribing information, USA, 1993
53. 53. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interleron beta-1b: experience during the first three years. Neurology 1996; 47: 889-94
54. 54. Pelkau J, White R. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing remitting multiple sclerosis. Mult Scler 1997; 3: 402
55. 55. Jacobs L, Munschauser FE. Treatment of multiple sclerosis with interferons. In: Rudick RA, Goodkin DE, editors. Treatment of multiple sclerosis: trial design, results and future perspectives. London: Springer, 1992: 223-50
56. 56. Alam J, McAllister A, Scaramucci J, et al. Pharmacokinetics and pharmacodynamics of inlerferon beta-1a (IFNβ-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 1997; 14: 35-43
57. 57. Alam J, Goelz S, Rioux P, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997; 14: 546-9
58. 58. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997; 49: 358-63
59. 59. Simon J, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87
60. 60. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72
61. 61. Salmon E, Le Cotonnee JY, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cytokine Res 1996; 16: 759-64
62. 62. PRISMS Study Group. The PRISMS study. Prevention of relapses and disability by interferon-beta 1a, Rebif®, subcutaneously in multiple sclerosis [poster]. 13th Congress of the European Committee for Treatment and Research in Mulliple Sclerosis (ECTRIMS): 1997 Nov 5; Istanbul, Turkey
63. 63. Amon R, Teitelbaum D. Suppression of demyelinating disease by synthetic copolymers. In: Serlupi Crescenzi G, editor. A multidisciplinary approach to myelin disease. New-York: Plenum, 1988: 234-50
64. 64. Teitelbaum D, Aharoni R, Arnon R, et al. Specific inhibition of the T-cell response to myelin basic protein by synthetic copolymer Cop 1. Proc Natl Acad Sci USA 1988; 85: 9724-8
65. 65. Teitelbaum D, Milo R, Arnon R, et al. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 1992; 89: 137-41
66. 66. Aharoni R, Teitelbaum D, Arnon R. T suppressor hybridomas and interleukin-2. dependent lines induced by copolymer 1 or spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur J Immunol 1993; 23: 17-25
67. 67. Aharoni R, Teitelbaum D, Arnon R, et al. Copolymer 1 inhibits the response to myelin basic protein p84-102 by T-cell receptor antagonism in addition to MHC blocking [abstract]. J Neurol Sci 1997; 150 Suppl.: S115
68. 68. Fridkis-Hareli M, Teitelbaum D, Gurevitch E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histoeompatibility complex molecules on living antigen presenting cells -specificity and promiscuity. Proc Natl Acad Sci U S A 1993; 91: 4872-6
69. 69. Racke MK, Martin R, McFarland H, et al. Copolymer-1-induced inhibition of antigen-specific T-cell activation: interference with antigen presentation. J Neuroimmunol 1992; 37: 75-84
70. 70. Fridkis-Hareli M, Teitelbaum D, Kerlero de Rosbo N, et al. Synthetic Copolymer 1 inhibits the binding of MBP, PLP and MOG peptides to class-II major histocompatibility complex molecules on antigen presenting cells [abstract]. J Neurochem 1994;63 Suppl. 1: S61
71. 71. Arnon R, Sela M, Teitelbaum D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol 1996; 243 Suppl. 1: S8-13
72. 72. Teitelbaum D, Fridkis-Hareli M, Arnon R, et al. Copolymer 1 inhibits the onset of chronic relapsing experimental autoimmune encephalomyelitis and interferes with T-cell response to encephalitogenic peptides of myelin proteolipid protein. J Neuroimmunol 1996; 64: 209-17
73. 73. Ben-Nun A, Mendel I, Bakimer R, et al. The autoimmune reactivity against myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer-1 on MOG-induced disease. J Neurol 1996; 243 Suppl.: S14-22
74. 74. Kerlero de Rosbo N, Mendel I, Milo R, et al. The autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis and MOG-induced experimental autoimmune encephalomyelitis: effect of copolymer-1 [abstract]. Eur J Neurol 1996; 3 Suppl. 4: 57
75. 75. Aharoni R, Teitelbaum D, Sela M, et al. Copolymer 1 induces T-cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelilis. Proc Natl Acad Sci U S A 1997; 94 (20): 10821-6
76. 76. Aharoni R, Teitelbaum D, Sela M, et al. Bystander suppression of proteolipid protein induced experimental autoimmune encephalomyelitis by Th2 suppressor cells specific to copolymer 1. J Neurol 1997; 244 Suppl. 3: S113-4
77. 77. Milo R, Kerlero de Rosbo N, Mendel I, et al. Suppression of the T-cell response to myelin oligodendrocyle glycoprotein by copolymer-1 [abstract]. Eur J Neurol 1996; 3 Suppl. 4: 33
78. 78. Lobel E, Riven-Kreitman R, Amsalem A, et al. Copolymer-1. Drugs Future 1996; 21:131-4
79. 79. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-14
80. 80. Bornstein MB, Miller A, Single S, et al. A placebo-controlled, double-blind, randomized, two center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533-9
81. 81. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701-8
82. 82. Ford CC, Brooks BR, Cohen JI, and the Copaxone Multiple Sclerosis Study Group. Sustained efficacy of glatiramer acetate for injection in a 5+ year trial of relapsing remitting MS [abstract]. Third Meeting of the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS): 1998 Oct 18; Montreal, Canada
83. 83. Johnson KP, and the Copolymer 1 Study Group. Efficacy of glatiramer acetate (Copaxone®) on multiple sclerosis disability is confirmed by analysis with the integrated disability status scale (IDSS) [abstract]. Neurology 1998; 50 Suppl. 4: A62-3
84. 84. Cohen JA, Grossman RI, Udupa JK, et al. assessment of the efficacy of copolymer-1 in the treatment of MS by quantitative MRI [abstract]. J Neuroimmunol 1995; Suppl. 1: 31
85. 85. Mancardi GL, Sardanelli F, Parodi RC, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998; 50: 1127-33
86. 86. Comi G, Filippi M, and the Capoxone MRI Study Group. The effect of glatiramer acetate (Capoxone®) on disease activity as measured by cerebral MRI in patients with relapsing remitting multiple sclerosis (RRMS): a multi-center, randomized, double blind, placebo-controlled study extended by open-label treatment [abstract]. 51st Annual Meeting of the American Academy of Neurology : 1999 Apr 21 ; Toronto, Canada
87. 87. Johnson KP, and The US Phase III Cupolymer 1 Study Group. Antibodies to copolymer 1 do not interfere with its clinical effect [abstract]. Ann Neurol 1995; 38: 973
88. 88. Report of the Quality Standard Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994; 44: 1537-40
89. 89. Munschauer FE, Stuart WH. Rationale for early treatment with Interferon beta-1a in relapsing-remitting multiple sclerosis. ClinTher 1997; 19: 868-82
90. 90. Freedman MS, for The Once Weekly Interferon for MS (OWIMS) Study Group. Dose-dependent clinical and MRI efficacy of interferon β-1a (Rebif®) in multiple sclerosis [works in progress abstract no. 9]. Annual Meeting of the American Neurological Association (ANA): 1988 Oct 19; Montreal, Quebec, Canada
91. 91. Goodkin DE. Interferon β therapy for multiple sclerosis [commentary]. Lancet 1998; 352: 1486-7